Superworth

Avantor AVTR

Medical - Diagnostics & Research, Healthcare
$15.61
−2.74%
Market cap
$10.6B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
1.6×
EV/EBIT
28.2×
Revenue, 12 months
$6.6B
−2% on a year ago
Net margin
−8.8%
Free cash flow yield
4.3%

Avantor trades at 1.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $6.6B over the last twelve months, down 2% on a year earlier with a −9% net margin.

Charts

Financials

Income statement for AVTR, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$1.7B−7%$1.7B−4%$1.7B−6%$1.7B−2%$1.7B−0%$1.7B−2%$1.6B−6%$1.7B−1%$1.6B−5%$1.7B−1%$1.6B+0%$1.7B+1%
Cost of revenue$1.1B−5%$1.2B−2%$1.1B−4%$1.1B−3%$1.1B+1%$1.1B−3%$1B−6%$1.1B+1%$1.1B−5%$1.1B+1%$1.1B+3%$1.2B+2%
Gross profit$578.6M−11%$570.4M−7%$570.5M−9%$581.5M−1%$564.4M−3%$562.9M−1%$534.9M−6%$554.1M−5%$526.5M−7%$523.9M−7%$500.7M−6%$537M−3%
SG&A$368.4M−2%$387.1M+7%$424.2M+8%$405.7M+14%$439.8M+19%$371.4M−4%$387.5M−9%$425.3M+5%$390.3M−11%$392.4M+6%$401.2M+4%$415.2M−2%
$210.2M−24%$183.3M−27%$146.3M−37%$175.8M+145%$124.6M−41%$638.1M+248%$147.4M+1%$128.8M−27%−$648.8M$126.4M−80%$99.5M−33%$121.8M−5%
Interest expense$72.4M+8%$65.3M−6%$64.3M−13%$60.9M−17%$48.7M−33%$44.9M−31%$42.2M−34%$43.4M−29%$44.2M−9%$40M−11%$42.9M+2%$39.4M−9%
Pre-tax income$136.5M−35%$119.5M−32%$80.6M−48%$114.6M$74.5M−45%$584.2M+389%$85.7M+6%$81.7M−29%−$689.5M$80.8M−86%$55.5M−35%$81.2M−1%
$28.1M−32%$21M−36%$20.2M−41%$21.7M+262%$16.7M−41%$83.8M+299%$21.2M+5%$17M−22%$22.3M+34%$28.4M−66%$12.2M−43%$43.1M+154%
Net income$108.4M−35%$98.5M−31%$60.4M−50%$92.9M$57.8M−47%$500.4M+408%$64.5M+7%$64.7M−30%−$711.8M$52.4M−90%$43.3M−33%$38.1M−41%
$0.16−36%$0.15−29%$0.09−50%$0.14$0.08−50%$0.73+387%$0.09+0%$0.09−36%−$1.04$0.08−89%$0.06−33%$0.06−33%
678.5M−0%679.3M+0%681.4M+1%682.6M+1%683M+1%681.3M+0%682.4M+0%681.8M−0%681.7M−0%678.2M−1%676.8M−1%677.2M−1%

Revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Income tax: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

EPS, diluted: 9 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. Q4 FY18: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 7 periods, Q4 FY19 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Diagnostics & Research nearest Avantor's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
AVTRAvantor$10.6Bn/m42.1×n/m1.6×−2%−8.8%
BIOBio-Rad Laboratories$9.8B44.4×30.9×n/m3.8×+1%8.6%
CAICaris Life Sciences$9.1B86.8×78.4×n/m9.2×+85%10.6%
RVTYRevvity$16.9B72.2×35.1×n/m5.8×+4%8.2%
LNTHLantheus$6.5B24.3×24.0×n/m4.2×+2%17.7%
MEDPMedpace$18.1B38.0×34.5×n/m6.5×+25%17.7%
BLLNBillionToOne$5.2B170×152×n/m13.1×+90%9.5%
CDNACareDx$4.5B35.9×19.2×n/m9.1×+39%25.9%
DGXQuest Diagnostics$27.5B24.9×19.3×n/m2.3×+9%9.5%
VCYTVeracyte$3.9B35.0×66.2×n/m7.0×+17%20.4%
LHLabcorp$28.9B29.4×19.5×18.8×2.0×+6%7.0%
Peer median$9.4B37.0×32.7×18.8×6.2×+13%10.1%

More on Avantor

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .